PacBio Appoints Recursion Co-founder Chris Gibson to Enhance AI-Driven Sequencing Analytics
PacBio appointed Christopher Gibson, Ph.D., co-founder and chairman of Recursion, to its Board of Directors to leverage his AI-driven drug discovery platform experience. His proven ability to integrate large-scale biological and machine learning tools aims to advance PacBio’s HiFi sequencing analytics and support future data-driven growth.
1. Board Appointment and Role
PacBio has added Christopher Gibson, Ph.D., to its Board of Directors. Gibson co-founded and chaired Recursion, driving its AI-native drug discovery platform from inception through public listing and strategic partnerships.
2. Gibson's AI and Data Expertise
At Recursion, Gibson oversaw integration of high-dimensional biology, automation and machine learning, building a proprietary platform that analyzes massive multimodal datasets for drug discovery and clinical applications.
3. Strategic Impact on HiFi Sequencing Analytics
PacBio expects Gibson’s background to accelerate development of advanced analytics for HiFi long-read sequencing datasets, enabling deeper insights and strengthening its position in genomics and data-driven life science research.